Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06196879 · ClinicalTrials.gov registry record · Phase 2

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

A Phase 2 study of Severe Asthma, sponsored by Upstream Bio.

Active
Registry status
Phase 2
Development phase
479
Enrollment target
20
Study locations

NCT06196879 is a Phase 2 study of Severe Asthma that is active but no longer recruiting, run by Upstream Bio. The registered enrollment target is 479 participants, below the 3,802-participant average among 9 other Severe Asthma trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06196879, a Phase 2 study of Severe Asthma, is active but no longer recruiting, sponsored by Upstream Bio.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
479 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability of verekitug (UPB-101) compared to placebo.

Conditions Studied

Severe Asthma

Interventions

  • DRUG Placebo
  • DRUG Verekitug (UPB-101)

Study Locations (20)

Florida

  • Advance Pharma Research - Cutler Bay
  • Unique Clinical Trials - Doral
  • Health and Life Research Institute, LLC - Miami
  • Phoenix Medical Research - Miami
  • Research Institute of South Florida - Miami
  • Nouvelle Clinical Research - Miami
  • Anderson Allergy And Asthma, PA - Orlando
  • Edward Jenner Research Group, LLC - Plantation
  • R&B Medical Center - Tampa
  • Clinical Site Partners dba Flourish research - Winter Park

California

  • Kern Research, Inc. - Bakersfield
  • Velocity Clinical Research - Lafayette LA - Los Angeles
  • Newport Native MD Inc - Newport Beach
  • California Medical Research Associates Inc. - Northridge
  • Integrated Research of Inland Inc - Upland
  • Allergy & Asthma Clinical Research - Walnut Creek
  • Allianz Research Institute - Westminster
  • Woodland Clinic Medical Group - Woodland

Alabama

  • AllerVie Clinical Research - Birmingham

Colorado

  • National Jewish Health - Denver

Trial Details

FieldValue
Enrollment Target 479 participants
Start Date 2024-02-27
Est. Completion 2026-06-11
Phase Phase 2

Sponsor

Upstream Bio

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06196879

The ClinicalTrials.gov registry entry for NCT06196879 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 479 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,802-participant average among 9 other Severe Asthma trials with a reported enrollment target (87% lower). The listed sponsor is Upstream Bio, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Severe Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06196879 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Alabama.

Frequently Asked Questions

What is clinical trial NCT06196879 about?

NCT06196879 is a clinical study titled "A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)". The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability o...

What is the current status of trial NCT06196879?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 479 participants. The study started on 2024-02-27. Estimated completion is 2026-06-11.

What conditions does trial NCT06196879 study?

This clinical trial studies the following conditions: Severe Asthma.

What interventions are being tested in trial NCT06196879?

The interventions under investigation include: Placebo (DRUG), Verekitug (UPB-101) (DRUG).

Who is sponsoring clinical trial NCT06196879?

This trial is sponsored by Upstream Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06196879 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Severe Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Severe Asthma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.